For example, MSLN positivity has been described in 38% to 69% of lung adenocarcinomas [37,38,39], 17% to 100% of pancreatic adenocarcinomas [40,41], 2% to 68% of colorectal carcinomas [5,9,42], 55% to 100% of serous carcinomas of the ovary [43,44], 21% to 78% of gastric adenocarcinomas [5,9,45], and 3% to 36% of breast carcinomas [9,46,47]. This evidence concerns the gene MSLN and lung adenocarcinoma.